Have a feature idea you'd love to see implemented?
Let us know!
CYCN Cyclerion Therapeutics Inc
Price (delayed)
$3.29
Market cap
$8.92M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.14
Enterprise value
$6.04M
Cyclerion Therapeutics is a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function. Cyclerion's lead program is CY6463, a novel, first-in-class, CNS-penetrant, sGC stimulator that modulates
Highlights
Cyclerion Therapeutics's EPS has soared by 59% YoY
The net income has surged by 51% year-on-year
The equity has contracted by 36% YoY and by 7% from the previous quarter
Key stats
What are the main financial stats of CYCN
Market
Valuations
Earnings
Shares outstanding
2.71M
Market cap
$8.92M
Enterprise value
$6.04M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.09
Price to sales (P/S)
42.84
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
31.16
Revenue
$194,000
Gross profit
$194,000
Net income
-$5.28M
EBIT
-$5.52M
EBITDA
-$5.52M
Free cash flow
-$6.23M
Per share
Balance sheet
Liquidity
EPS
-$2.14
EPS diluted
-$2.14
Free cash flow per share
-$2.47
Book value per share
$3.02
Revenue per share
$0.08
TBVPS
$3.52
Total assets
$8.9M
Total liabilities
$700,000
Debt
$0
Equity
$8.2M
Working capital
$2.85M
Debt to equity
0
Current ratio
5.07
Quick ratio
4.17
Net debt/EBITDA
0.52
Margins
Efficiency
Dividend
EBITDA margin
-2,845.4%
Gross margin
100%
Net margin
-2,722.2%
Operating margin
-3,054.1%
Return on assets
-48.3%
Return on equity
-55.3%
Return on invested capital
-126.4%
Return on capital employed
-67.3%
Return on sales
-2,845.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CYCN stock price
How has the Cyclerion Therapeutics stock price performed over time
Intraday
2.17%
1 week
-0.9%
1 month
40.6%
1 year
-6%
YTD
2.17%
QTD
2.17%
Financial performance
How have Cyclerion Therapeutics's revenue and profit performed over time
Revenue
$194,000
Gross profit
$194,000
Operating income
-$5.93M
Net income
-$5.28M
Gross margin
100%
Net margin
-2,722.2%
The operating income has soared by 62% YoY and by 45% from the previous quarter
The net income has surged by 51% year-on-year
Growth
What is Cyclerion Therapeutics's growth rate over time
Valuation
What is Cyclerion Therapeutics stock price valuation
P/E
N/A
P/B
1.09
P/S
42.84
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
31.16
Cyclerion Therapeutics's EPS has soared by 59% YoY
The stock's price to book (P/B) is 41% less than its 5-year quarterly average of 1.8 but 33% more than its last 4 quarters average of 0.8
The equity has contracted by 36% YoY and by 7% from the previous quarter
Efficiency
How efficient is Cyclerion Therapeutics business performance
The company's return on equity has surged by 58% YoY
CYCN's return on assets is up by 39% year-on-year
Dividends
What is CYCN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CYCN.
Financial health
How did Cyclerion Therapeutics financials performed over time
Cyclerion Therapeutics's total liabilities has plunged by 70% YoY and by 45% from the previous quarter
Cyclerion Therapeutics's total assets has decreased by 42% YoY and by 12% from the previous quarter
Cyclerion Therapeutics's debt is 100% less than its equity
The equity has contracted by 36% YoY and by 7% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.